AstraZeneca (AZN)

Sector:

Pharma and Biotech

Index:

FTSE 100

Trade now with BarclaysStockbrokers Trade now with Barclays Sponsored by Barclays Stockbrokers

4,662.50p
   
  • Change Today:
      96.50p
  • 52 Week High: 5,220.00
  • 52 Week Low: 3,774.00
  • Currency: UK Pounds
  • Shares Issued: 1,265.60m
  • Volume: 2,093,270
  • Market Cap: 59,009m
  • RiskGrade: 90
  • Beta: 0.88

Deal with Barclays Trade now with Barclays Stockbrokers

AstraZeneca Overview

A world-leading pharmaceutical group, AstraZeneca was created in 1999 via the merger of Sweden's Astra and the UK's Zeneca, which had been demerged from chemicals group ICI in 1993. About half of its total sales are generated from the US, with over a third of revenues coming from its gastrointestinal treatments such as Prilosec (Losec) and Nexium.

1 Day Chart

6 Month Chart

AstraZeneca Financials

Latest F'cast
Div Yield 4.7% 4.8%
Div Cover 1.5 1.3
Op Mrgn 23.0% 25.4%
ROCE n/a  
Latest F'cast
P/E 13.8 15.5
PEG 11.8 n/a
Pr/Revenue 3.5 3.4
Pr/Book 4.5  
Latest F'cast
Revenue -9.8% -37.2%
PBT 15.7% -4.1%
EPS 1.2% -12.9%
DPS n/a -38.2%

AstraZeneca Fundamentals

Year Ending Revenue ($m) Pre-tax ($m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-12 27,973.00 7,646.00 683.00¢ 5.5 n/a -6% 280.00¢ 7.5%
31-Dec-13 25,711.00 3,267.00 505.00¢ 9.1 n/a -26% 280.00¢ 6.1%
31-Dec-14 26,095.00 1,246.00 428.00¢ 13.6 n/a -15% 280.00¢ 4.8%
31-Dec-15 23,641.00 3,069.00 426.00¢ 13.9 n/a -0% 280.00¢ 4.7%
31-Dec-16 21,319.00 3,552.00 431.00¢ 13.2 13.2 +1% 280.00¢ 4.9%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

AstraZeneca Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-17 17,127.78 4,357.75 292.97p 15.9 n/a -13% 221.44p 4.8%
31-Dec-18 17,788.16 4,649.27 316.58p 14.7 1.8 +8% 223.57p 4.9%

Copyright © 2017 FactSet Research Systems Inc. All rights reserved.

AstraZeneca Company Announcements

Notification of Major Interest in Shares 12-Apr-2017 17:34 RNS
Total Voting Rights 03-Apr-2017 15:00 RNS
Tagrisso (osimertinib) receives FDA full approval 31-Mar-2017 07:01 RNS

Latest AstraZeneca Director Deals

Traded Action Notifier PriceAmountValue
28-Mar-17 Transfer From Pascal Soriot 0.000p 101,584 0.00
28-Mar-17 Transfer From Marc Dunoyer 0.000p 25,478 0.00
28-Mar-17 Transfer From Marc Dunoyer 0.000p 1,419 0.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

AstraZeneca Market Data

Currency UK Pounds
Share Price 4,662.50p
Change Today 96.50p
% Change 2.11 %
52 Week High 5,220.00
52 Week Low 3,774.00
Volume 2,093,270
Shares Issued 1,265.60m
Market Cap 59,009m
Beta 0.88
RiskGrade 90

AstraZeneca Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
32% below the market average32% below the market average32% below the market average32% below the market average32% below the market average
35.59% above the sector average35.59% above the sector average35.59% above the sector average35.59% above the sector average35.59% above the sector average
Price Trend
41.4% below the market average41.4% below the market average41.4% below the market average41.4% below the market average41.4% below the market average
14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average14.29% above the sector average
Income
75.59% above the market average75.59% above the market average75.59% above the market average75.59% above the market average75.59% above the market average
66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average66.67% above the sector average
Growth
53.5% below the market average53.5% below the market average53.5% below the market average53.5% below the market average53.5% below the market average
73.33% below the sector average73.33% below the sector average73.33% below the sector average73.33% below the sector average73.33% below the sector average

What The Brokers Say

Strong Buy 20
Buy 2
Neutral 13
Sell 0
Strong Sell 5
Total 40
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

AstraZeneca Dividends

  Latest Previous
  2nd Interim 1st Interim
Ex-Div 16-Feb-17 11-Aug-16
Paid 20-Mar-17 12-Sep-16
Amount 190.00¢ 90.00¢

Trades for 24-Apr-2017

Time Volume / Share Price
17:08 810 @ 4,645.34p
17:08 229 @ 4,645.24p
17:08 1,610 @ 4,645.24p
17:08 5,493 @ 4,645.24p
17:03 342 @ 4,646.00p

Top of Page